Literature DB >> 6515598

Short term variability in FEV1: relation to pretest activity, level of FEV1, and smoking habits.

P M Tweeddale, S Merchant, M Leslie, F Alexander, G J McHardy.   

Abstract

The natural variability in forced expiratory volume in one second (FEV1) over 20 minutes was determined in 54 fit hospital employees and 13 patients with restrictive lung disorders. Initial FEV1 ranged from 1.1 to 6.3 1 BTPS. Variability when expressed as absolute change was similar at all levels of FEV1, so that, when expressed as percentage change, variability decreased with increasing FEV1. Smoking habits did not appear to affect variability but activity before the test did. On the basis of these results an absolute change in FEV1 of 190 ml would be necessary for 95% confidence that the change in FEV1 occurred other than by chance in any one individual. This suggests that the absolute change in FEV1 might be a more reliable criterion than percentage change when distinguishing between natural variability and a response to inhalation of bronchodilators.

Entities:  

Mesh:

Year:  1984        PMID: 6515598      PMCID: PMC459955          DOI: 10.1136/thx.39.12.928

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  8 in total

1.  Variability of routine pulmonary function tests.

Authors:  J Hruby; J Butler
Journal:  Thorax       Date:  1975-10       Impact factor: 9.139

2.  Random error with the FEV1 = case for absolute values.

Authors:  J R Vale; A Gulsvik; J Kongerud
Journal:  Lancet       Date:  1981-08-08       Impact factor: 79.321

3.  Absolute FEV1 values.

Authors:  J E Cotes
Journal:  Lancet       Date:  1981-08-22       Impact factor: 79.321

4.  Estimation of the FEV.

Authors:  P D Oldham; T J Cole
Journal:  Thorax       Date:  1983-09       Impact factor: 9.139

5.  How many blows really make an FEV1, FVC, or PEFR?

Authors:  M I Ullah; V Cuddihy; K B Saunders; G J Addis
Journal:  Thorax       Date:  1983-02       Impact factor: 9.139

6.  Epidemiology Standardization Project (American Thoracic Society).

Authors:  B G Ferris
Journal:  Am Rev Respir Dis       Date:  1978-12

7.  Assessment of ventilatory abnormality in the asymptomatic subject: an exercise in futility.

Authors:  B J Sobol
Journal:  Thorax       Date:  1966-09       Impact factor: 9.139

8.  Within-subject variability and per cent change for significance of spirometry in normal subjects and in patients with cystic fibrosis.

Authors:  B G Nickerson; R J Lemen; C B Gerdes; M J Wegmann; G Robertson
Journal:  Am Rev Respir Dis       Date:  1980-12
  8 in total
  12 in total

1.  ARTP statement on pulmonary function testing 2020.

Authors:  Karl Peter Sylvester; Nigel Clayton; Ian Cliff; Michael Hepple; Adrian Kendrick; Jane Kirkby; Martin Miller; Alan Moore; Gerrard Francis Rafferty; Liam O'Reilly; Joanna Shakespeare; Laurie Smith; Trefor Watts; Martyn Bucknall; Keith Butterfield
Journal:  BMJ Open Respir Res       Date:  2020-07

2.  Short term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects.

Authors:  P M Tweeddale; F Alexander; G J McHardy
Journal:  Thorax       Date:  1987-07       Impact factor: 9.139

3.  Estimation and repeatability of the response to inhaled histamine in a community survey.

Authors:  S Chinn; J R Britton; P G Burney; A E Tattersfield; A O Papacosta
Journal:  Thorax       Date:  1987-01       Impact factor: 9.139

4.  Can peak expiratory flow measurements reliably identify the presence of airway obstruction and bronchodilator response as assessed by FEV(1) in primary care patients presenting with a persistent cough?

Authors:  H A Thiadens; G H De Bock; J C Van Houwelingen; F W Dekker; M W De Waal; M P Springer; D S Postma
Journal:  Thorax       Date:  1999-12       Impact factor: 9.139

5.  Dose-response relationship and time-course of the effect of inhaled magnesium sulphate on airflow in normal and asthmatic subjects.

Authors:  J Hill; J Britton
Journal:  Br J Clin Pharmacol       Date:  1995-12       Impact factor: 4.335

6.  Variability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease. Dutch CNSLD Study Group.

Authors:  H A Kerstjens; P L Brand; P H Quanjer; B A van der Bruggen-Bogaarts; G H Koëter; D S Postma
Journal:  Thorax       Date:  1993-07       Impact factor: 9.139

7.  Effect of increasing doses of beta agonists on spirometric parameters, exercise capacity, and quality of life in patients with chronic airflow limitation.

Authors:  R Jaeschke; G H Guyatt; A Willan; D Cook; S Harper; J Morris; H Ramsdale; R Haddon; M Newhouse
Journal:  Thorax       Date:  1994-05       Impact factor: 9.139

8.  Validity of peak expiratory flow measurement in assessing reversibility of airflow obstruction.

Authors:  F W Dekker; A C Schrier; P J Sterk; J H Dijkman
Journal:  Thorax       Date:  1992-03       Impact factor: 9.139

9.  Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group.

Authors:  P L Brand; P H Quanjer; D S Postma; H A Kerstjens; G H Koëter; P N Dekhuijzen; H J Sluiter
Journal:  Thorax       Date:  1992-06       Impact factor: 9.139

10.  Worldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease study.

Authors:  Wan C Tan; William M Vollmer; Bernd Lamprecht; David M Mannino; Anamika Jithoo; Ewa Nizankowska-Mogilnicka; Filip Mejza; Thorarinn Gislason; Peter G J Burney; A Sonia Buist
Journal:  Thorax       Date:  2012-04-29       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.